PMS45 Cost-Utility and Budget Impact Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis in Greece
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.431
https://www.valueinhealthjournal.com/article/S1098-3015(11)01993-0/fulltext
Title :
PMS45 Cost-Utility and Budget Impact Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01993-0&doi=10.1016/j.jval.2011.08.431
First page :
A310
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
404